Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Takara, Ayako ^a   Ogawa, Hiroshi ^b   Endoh, Yasuhiro ^a   Mori, Fumiaki ^b   Yamaguchi, Jun ichi ^b   Takagi, Atsushi ^b   Koyanagi, Ryo ^b   Shiga, Tsuyoshi ^b   Kasanuki, Hiroshi ^b   Hagiwara, Nobuhisa ^b  

^a Saiseikai Kurihashi Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY THROMBOLYSIS; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DIABETIC ANGIOPATHY; HEART INFARCTION; METHODOLOGY; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL; SURVIVOR;

CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS;

EID: 76349090431     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-1     Document Type: Article

References (24)

1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, . American College of Cardiology; American Heart Association; Canadian Cardiovascular Society ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004, 44(3):671-719. 10.1016/j.jacc.2004.07.002, 15358045, American College of Cardiology; American Heart Association; Canadian Cardiovascular Society.
2. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998, 317(7160):713-720. 28660, 9732338, UK Prospective Diabetes Study Group.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234. 10.1056/NEJM199807233390404, 9673301.
4. Kasanuki H, Honda T, Haze K, Sumiyoshi T, Horie T, Yagi M, Yamaguchi J, Ishii Y, Fujii SY, Nagashima M, Okada H, Koganei H, Koyanagi R, Tsurumi Y, Kimura H, Ogawa H, . HIJAMI Investigators A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry. Am Heart J 2005, 150(3):411-418. 10.1016/j.ahj.2004.10.001, 16169317, HIJAMI Investigators.
5. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36(3):959-969. 10.1016/S0735-1097(00)00804-4, 10987628.
6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
7. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17(19):2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B, 9802183.
8. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996, 52(1):249-264. 10.2307/2533160, 8934595.
9. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28(9):2130-2135. 10.2337/diacare.28.9.2130, 16123478.
10. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414(6865):782-787. 10.1038/414782a, 11742409.
11. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996, 94(8):1818-1825.
12. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004, 109(4):476-480. 10.1161/01.CIR.0000109693.64957.20, 14732749.
13. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996, 335(4):217-225. 10.1056/NEJM199607253350401, 8657237, The Bypass Angioplasty Revascularization Investigation (BARI) Investigators.
14. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, Wong CK, Stewart JT, Aylward PE, Wong SC, Hochman JS. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 2005, 112(13):1992-2001. 10.1161/CIRCULATIONAHA.105.540948, 16186436.
15. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation 1993, 87(2):659-675.
16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol 1988, 12(6 Suppl A):3A-13A. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
17. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300(18):2134-2141. 10.1001/jama.2008.623, 18997198.
18. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840. 10.1136/bmj.a1840, 2658865, 18927173.
19. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371(9607):117-125. 10.1016/S0140-6736(08)60104-X, 18191683.
20. Australia/New Zealand Heart Failure Research Collaborative Group Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997, 349(9049):375-380. 10.1016/S0140-6736(97)80008-6, 9033462, Australia/New Zealand Heart Failure Research Collaborative Group.
21. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999, 33(6):1442-1452. 10.1016/S0735-1097(99)00073-X, 10334407.
22. Nagashima M, Koyanagi R, Kasanuki H, Hagiwara N, Yamaguchi J, Atsuchi N, Honda T, Haze K, Sumiyoshi T, Urashima M, et al. Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). Am J Cardiol 2007, 99(11):1523-1528. 10.1016/j.amjcard.2007.01.024, 17531574.
23. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820. 10.1038/414813a, 11742414.
24. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399(6736):597-601. 10.1038/21218, 10376602.